CEO: Sumit Aggarwal

Advent Contact: Raj Parekh

Platform for novel RNA-modulating drug candidates for rare, nonsense mutation-driven diseases including Cystic Fibrosis

Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate in the early stages of clinical development focusing on cystic fibrosis. In addition, Eloxx’s innovative TURBO-ZM™ chemistry technology platform provides a pipeline of novel Ribosome Modulating Agents (RMAs) as orally available therapeutics to target select rare diseases including inherited diseases and cancers.

Zikani Therapeutics Completes Series A-1 Funding

Eloxx Pharmaceuticals acquired Zikani Therapeutics, an Advent portfolio company, in 2021. Eloxx is listed on NASDAQ